Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 6 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
The Ludwig Institute for Cancer Research Ltd. is currently managing 9 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 9 actions are distributed among 9 distinct examiners, meaning that every active case is being reviewed by a different individual. This high level of dispersion indicates a broad prosecution strategy that avoids concentration with any single examiner. Furthermore, the portfolio spans 6 distinct art units, reflecting the diverse and specialized nature of the institute's cancer research.
The busiest examiner, TRAN, ERIC, is responsible for 1 pending office action, which is consistent with the even distribution across the 9 distinct examiners. With 9 pending office actions in total, the institute must navigate 9 unique examination styles and sets of feedback. The presence of 6 distinct art units suggests that the company's innovations are being evaluated under a variety of technical standards. Practitioners should be prepared for a wide range of examiner perspectives and should tailor their responses to the specific requirements of each of the 6 art units involved.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (25%) |
| Double-patenting + other | 2 (25%) |
| Multi-statute (no §101) | 4 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TRAN, ERIC | 1 | 70.8% | +23.3% |
| RILEY, JEZIA | 1 | 82.9% | +7.3% |
| KIM, SEONG JONG | 1 | 25.0% | +0.0% |
| STAVROU, CONSTANTINA E | 1 | 43.7% | +36.9% |
| ROGERS, ERIC JASON | 1 | 57.4% | +32.6% |
| KIM, TAEYOON | 1 | 51.5% | +52.1% |
| PHAM, KHAI QUYNH TIEN | 1 | 0.0% | +0.0% |
| BAUSCH, SARAE L | 1 | 29.8% | +44.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18781157 | BISULFITE-FREE, BASE-RESOLUTION IDENTIFICATION OF CYTOSINE MODIFICATIONS | RILEY, JEZIA | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17746748 | METHODS AND COMPOSITIONS FOR DETECTING ecDNA | BAUSCH, SARAE L | 243d overdue |
| 18836884 | USE OF UROLITHIN IN THE REMISSION PHASE OF A PRECEDING CANCER THERAPY | TRAN, ERIC | — |
| 18579221 | Use Of Methanol And Prodrugs Thereof In Therapy | KIM, SEONG JONG | — |
| 18558802 | UROLITHIN FOR INCREASING STEM CELL FUNCTION | STAVROU, CONSTANTINA E | — |
| 18001898 | PARALLEL ANALYSIS OF INDIVIDUAL CELLS FOR RNA EXPRESSION AND DNA FROM TARGETED TAGMENTATION BY SEQUENCING | PHAM, KHAI QUYNH TIEN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17746748 | METHODS AND COMPOSITIONS FOR DETECTING ecDNA | BAUSCH, SARAE L | 243d overdue |
| 18246744 | COMPOSITIONS AND METHODS FOR INCREASING STEM CELL FUNCTION | ROGERS, ERIC JASON | 2d overdue |
| 18836884 | USE OF UROLITHIN IN THE REMISSION PHASE OF A PRECEDING CANCER THERAPY | TRAN, ERIC | — |
| 18558802 | UROLITHIN FOR INCREASING STEM CELL FUNCTION | STAVROU, CONSTANTINA E | — |
| 18246710 | COMPOSITIONS AND METHODS FOR INCREASING STEM CELL FUNCTION | KIM, TAEYOON | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| 1632 | 1 |
| 1638 | 1 |
| 1631 | 1 |
| 1684 | 1 |
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18836884 | USE OF UROLITHIN IN THE REMISSION PHASE OF A PRECEDING CANCER THERAPY | TRAN, ERIC | — | §103§112 | Non-Final OA | — | Pending | Aug 08, 2024 |
| 18781157 | BISULFITE-FREE, BASE-RESOLUTION IDENTIFICATION OF CYTOSINE MODIFICATIONS | RILEY, JEZIA | — | §103Other | Non-Final OA | — | Pending | Jul 23, 2024 |
| 18579221 | Use Of Methanol And Prodrugs Thereof In Therapy | KIM, SEONG JONG | 1621 | §103§112 | Non-Final OA | — | Pending | Jan 12, 2024 |
| 18558802 | UROLITHIN FOR INCREASING STEM CELL FUNCTION | STAVROU, CONSTANTINA E | 1632 | §102§103§112Other | Non-Final OA | — | Pending | Nov 03, 2023 |
| 18246744 | COMPOSITIONS AND METHODS FOR INCREASING STEM CELL FUNCTION | ROGERS, ERIC JASON | 1638 | §103§112DP | Final Rejection | 2d overdue | Pending | Mar 27, 2023 |
| 18246710 | COMPOSITIONS AND METHODS FOR INCREASING STEM CELL FUNCTION | KIM, TAEYOON | 1631 | §103DP | Non-Final OA | — | Pending | Mar 27, 2023 |
| 18001898 | PARALLEL ANALYSIS OF INDIVIDUAL CELLS FOR RNA EXPRESSION AND DNA FROM TARGETED TAGMENTATION BY SEQUENCING | PHAM, KHAI QUYNH TIEN | 1684 | §103 | Non-Final OA | — | Pending | Dec 15, 2022 |
| 17746748 | METHODS AND COMPOSITIONS FOR DETECTING ecDNA | BAUSCH, SARAE L | 1699 | §103§112 | Final Rejection | 243d overdue | Pending | May 17, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial